By Jared S. Hopkins
Merck & Co. said Kenneth Frazier, its chairman and chief
executive, is retiring as CEO at the end of June.
The Kenilworth, N.J., drugmaker said Thursday that Robert Davis,
currently executive vice president of global services and chief
financial officer, will succeed Mr. Frazier in the top job on July
1.
"It has been a distinct honor and privilege to serve this great
company as its CEO over the past decade," Mr. Frazier, 66 years
old, said on the company's earnings call Thursday.
Under Mr. Frazier's leadership, Merck became a leader in the
emerging field of cancer immunotherapy and in the development of
the drug Keytruda, now one of its top sellers. The therapy, which
treats lung and other cancers, totaled more than $14 billion in
global sales last year.
Keytruda's success has lifted Merck's market capitalization to a
record high $234 billion last year but has come down slightly.
Since the company released positive study results for Keytruda in
April 2018, Merck shares are up more than 35%, compared with the
S&P 500's nearly 48% gain.
Mr. Frazier, a lawyer who has led Merck since 2011, is among the
few Black CEOs at S&P 500 companies and has been a leading
industry voice in recent years encouraging companies to hire more
Black employees. He has also steered Merck through criticism from
politicians and patients about how the industry prices its
medications.
Mr. Frazier's exit was anticipated after the board allowed him
to remain CEO three years ago, waiving the requirement that the
company's chief retire at 65.
Merck's board considered internal and external candidates, but
the finalists were all Merck executives: Mr. Davis, Mike Nally,
chief marketing officer, and Frank Clyburn, chief commercial
officer, according to people familiar with the matter.
Just four of the chief executives of America's top 500 companies
-- or 1% -- are Black, including Mr. Frazier. The others are Marvin
Ellison of big-box hardware store Lowe's Cos., Roger Ferguson Jr.
of the financial-services firm Teachers Insurance and Annuity
Association of America and René Jones, who runs M&T Bank in New
York. When Rosalind Brewer takes the helm in March of Walgreens
Boots Alliance Inc., the number will rise briefly to five, as
TIAA's Mr. Ferguson is set to retire at the end of the month.
Despite Keytruda's success, some investors and analysts have
worried that Merck's growth might depend on the therapy too
heavily. The drugmaker has done deals for small companies to
augment its pipeline in the past couple of years, and it plans to
spin off some slow-growth legacy products.
The selection of Mr. Davis, 54, likely signals intensified
business development to reduce the company's dependency on
Keytruda, according to a Thursday note from Citigroup Inc. analyst
Andrew Baum. Keytruda sales made up nearly one-third of the
company's approximate $48 billion in revenue last year, Merck said
Thursday.
Still, Mr. Davis's elevation suggests Merck's overall strategy
is likely to remain steady in the short term, said Seamus
Fernandez, an analyst at Guggenheim Securities LLC, although he
added that "part of me wonders if this is a way to speed up and
accelerate decision-making" for deals.
A graduate of Harvard Law School, Mr. Frazier worked at law firm
Drinker Biddle & Reath before joining Merck in 1992. He became
general counsel in 1999 and defended Merck from allegations that
its top-selling painkiller Vioxx increased the risk of heart
attacks and strokes. Merck agreed in 2007 to pay $4.85 billion to
settle thousands of claims.
Issues of race and the workplace have been important to Mr.
Frazier, who last month helped start a nonprofit organization with
other CEOs to connect employers with Black workers.
He has also taken on delicate, sometimes controversial topics
during his tenure atop Merck, ranging from drug pricing to former
President Donald Trump. Mr. Frazier stepped down from a White House
business committee in 2017, calling his decision a matter of
conscience after Mr. Trump blamed both sides for deadly clashes
between white supremacists and counterprotesters in
Charlottesville, Va.
One of Mr. Frazier's key moves early on was bringing back Roger
Perlmutter to Merck in 2013 to lead its R&D. Dr. Perlmutter has
since been credited with reviving the company's labs after several
setbacks.
Dr. Perlmutter retired in December, turning the research reins
over to Dean Li.
Keytruda's patent protection is set to expire by the end of
2028, and the focus will be on Merck's pipeline and potential deals
to spur growth, analysts say.
Merck's roster of experimental drugs include vaccines, including
a potential competitor to Pfizer Inc.'s big-selling Prevnar
vaccine, which protects against infections such as pneumonia and
meningitis. The vaccine could fetch at least $1 billion, according
to analyst Gregg Gilbert of Truist Securities Inc.
Merck also is developing treatments for HIV/AIDS and oncology.
Two experimental Covid-19 drugs could drive short-term sales with
results expected soon, according to analysts.
Merck said Mr. Davis, who joined the company as CFO in 2014,
will become president on April 1, at which time the drugmaker's
four operating divisions will begin reporting to him. Before
joining Merck Mr. Davis held roles at Baxter International Inc. and
Eli Lilly & Co.
Mr. Davis is joining a small group of chief financial officers
who ascended to the top spot. Around 6% CFOs have been promoted to
chief executive officers at companies in the S&P 500 and
Fortune 500 in recent years, according to the Crist|Kolder
Volatility Report. The most common path is an internal promotion
from the role of chief operating officer.
In reporting fourth-quarter earnings Thursday, Merck said it
expects total revenue this year of between $51.8 billion and $53.8
billion and adjusted earnings of $6.48 to $6.68 a share.
Analysts had been forecasting revenue of $51.66 billion and an
adjusted profit of $6.30 a share.
Merck's quarterly revenue of $12.5 billion was up 5% from $11.9
billion in the year-earlier quarter, as Keytruda sales rose nearly
one-third to around $4 billion. Analysts surveyed by FactSet were
expecting revenue of $12.67 billion in the latest period.
--Lynn Cook and Nina Trentmann contributed to this article.
Write to Jared S. Hopkins at jared.hopkins@wsj.com
(END) Dow Jones Newswires
February 04, 2021 16:59 ET (21:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024